Turning Chemopreventive Agents Against Breast Cancer: Sensitizing Cancers to Therapeutics While Protecting Normal Tissues from Toxicity

Abstract

The chemopreventive agent, sulforaphane (SFN) induces, Nfr-2-stabilization and Nrf2-dependent transcription in breast cancer cells. These effects of SFN are dependent upon PKC and PI3K/AKT pathways as well as the likely involvement of direct interactions between SFN and Keapl. SFN sensitizes breast cancer cells to the cytotoxicities of doxorubicin and peclitaxel. Co-treatment with the PKC inhibitor, Ro-31-8221, but not the PI3K inhibitor, LY294002, augments this sensitization by SFN. However, the utility of combined chemopreventive agent (SFN). And cancer drug (doxorubicin and paclitaxel treatment in breast cancer is potentially limited because SFN also sensitizes some non-cancerous cells to cancer drug toxicity.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Jul 01, 2012
Accession Number
ADA589289

Entities

People

  • Charles S. Morrow

Organizations

  • Wake Forest University

Tags

DTIC Thesaurus Topics

  • Abstracts
  • Biomedical Research
  • Breast Cancer
  • Department Of Defense
  • Drug Therapy
  • Information Operations
  • Inhibitors
  • Instructions
  • Maryland
  • Neoplasms
  • Therapy
  • Toxicity
  • Universities

Fields of Study

  • Chemistry
  • Medicine

Readers

  • Allergy and Immunology.
  • Cellular and Molecular Pathways of Apoptosis.
  • Oncology (Cancer Research).

Technology Areas

  • Biotechnology
  • Biotechnology - Cancer Biotech